Cancer Drug News Issue 674

Description: 2015 FDA novel cancer drug approvals highlighted high innovation levels, but it was just an indication of the potential yet to be unlocked within the field. FDA novel approval rates will increase considerably with the purging of pipelines containing high numbers of targeted cancer agents. Stratification of diseases through better genomic understanding and diagnostic techniques will corroborate the FDA’s support for expedited review times for promising novel agents, and we should see record approval times persist. Orphan drug parameters may face changes as the healthcare system ultimately struggles to deal with the deluge of eligible drugs.

Contents:

1 Transforming Cancer Treatment Paradigms Will Drive Record FDA Approvals
   - Breast Cancer
4 Puma Delays Filing Neratinib NDA In Advanced BC
   - Haematological Cancer
4 FDA Rejects Bendeka's Orphan Drug Exclusivity In CLL/NHL
4 EMA Validates BMS' Application For Opdivo To Treat cHL
5 CHMP Adopts Positive Opinion On Darzalex To Treat r/r MM
5 Aplidin To Be Filed Following Positive Results In Phase III Study
   - Lung Cancer
5 Argos Initiates Phase II Trial Of Lung Cancer Immunotherapy
5 Lung Cancer Sub-Classification Drives Highly Personalised Treatment
6 Tagrisso Approved In Japan To Treat EGFr T790M Mutation-Positive Metastatic NSCLC
   - Genito-Urinary Cancer
7 Xtandi Phase III Trial Initiated In mHSPCA
7 First Patient Enrolled In Second Stage Of Onapristone Phase I/II CRPCA Trial
7 Xofigo Approved For Sale In Japan To Treat CRPCA
   - Gynaecological Cancer
8 FDA Fast Track Designation For OXiGENE's CA4P In Advance OC
   - Gastrointestinal Cancer
8 OXiGENE Secures European ODD For CA4P To Treat NETs
8 EMA Validates Xilonix MAA
   - Melanoma/Skin Cancer
8 FDA ODD For Adaptimmune's T-Cell Therapy Targeting NY-ESO To Treat STS
   - General Developments
9 Disease Interception Represents Paradigm Shift For Healthcare
10 ADC Partnership Potential Boosted With Payload Technology
   - Supportive Therapies
11 Helsinn/Eisai Amend CINV Collaboration Franchise In US
   - Corporate Activity
12 Zymeworks Completes Merger/Acquisition Of Kairos Therapeutics
12 Amal Secures Funding To Develop Novel Therapeutic Cancer Vaccine
12 Dr Reddy's Gains E7777 Rights For EU, US And Certain Emerging Markets From Eisai

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3758116/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct.

Product Name: Cancer Drug News Issue 674
Web Address: http://www.researchandmarkets.com/reports/3758116/
Office Code: SCD22DKP

Product Format
Please select the product format and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Electronic (PDF) - Single User:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>USD 1252</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  
Mr ☐  Mrs ☐  Dr ☐  Miss ☐  Ms ☐  Prof ☐
First Name: ___________________________  Last Name: ___________________________
Email Address: * _______________________
Job Title: ___________________________
Organisation: _________________________
Address: _____________________________
City: ________________________________
Postal / Zip Code: ____________________
Country: _____________________________
Phone Number: ________________________
Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World